Lung & Respiratory Updates: Fibrosis, COPD, Asthma & More
Get the latest insights in under 5 minutes on key developments reshaping the future of lung and respiratory care. From promising anti-fibrotic compounds to major regulatory greenlights in asthma and COPD—this week’s updates spotlight the global momentum in respiratory health research.
🌟 IPF & Autoimmune ILD Breakthrough: Nuformix’s NXP002 shows strong anti-fibrotic effects in patient-derived lung tissue, reducing pro-fibrotic biomarkers and enhancing synergy with standard-of-care treatments.
💉 Tezepelumab Gets Phase III Approval in India: AstraZeneca’s monoclonal antibody targeting TSLP for severe asthma moves ahead, following approval by CDSCO and endorsement in the March 2025 SEC Pulmonary review.
🔬 Sanofi Pipeline Pushes Forward: Amlitelimab demonstrates durable effects in asthma, while Itepekimab and Lunsekimig enter expanded trials for COPD and sinusitis—highlighting the potential for sustained disease control through infrequent dosing.
🌬️ Zydus COPD Combo Trial Approved: Glycopyrronium + Indacaterol MDI combination receives CDSCO clearance for Phase III in India. Early data shows rapid bronchodilation within 5 minutes and long-acting therapeutic impact.
📢 Stay Ahead in Lung & Respiratory Health Research!
✅ Like, share, and subscribe for weekly updates on Lung & Respiratory Health
#LungHealth #IPF #ILD #AsthmaResearch #COPD #Tezepelumab #Sanofi #Zydus #ClinicalTrials #RespiratoryMedicine #BiopharmaNews #FibrosisTreatment #Biologics #HealthcareInnovation #LucidQuest #PulmonaryCare #InhalationTherapies #TSLP #NXP002 #LungResearch #RespiratoryTherapies #IndiaClinicalTrials #PharmaUpdates